Matthew Biegler Analyst PerformanceAnalyst at OppenheimerMatthew Biegler is a stock analyst at Oppenheimer focused in the medical sector, covering 17 publicly traded companies. Over the past year, Matthew Biegler has issued 23 stock ratings, including and buy recommendations. While full access to Matthew Biegler's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Matthew Biegler's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings38 Last 6 YearsBuy Recommendations97.37% 37 Buy RatingsCompanies Covered17 Unique Companies Ratings Distribution38RatingsDistribution of strong buy, buy, hold, and sell ratings by Matthew Biegler.RatingPercentageCount Strong Buy0.0%0 ratings Buy97.4%37 ratings Hold2.6%1 ratings Sell0.0%0 ratingsOut of 38 total stock ratings issued by Matthew Biegler at Oppenheimer, the majority (97.4%) have been Buy recommendations, followed by 2.6% Hold.Best & Worst CallsBest Call0000.0%OLMAMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%PRTGNov 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ17 companiesMatthew Biegler, an analyst at Oppenheimer, currently covers 17 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical16 companies94.1%Manufacturing1 company5.9%Matthew Biegler of Oppenheimer specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE12 companies70.6%MED - DRUGS3 companies17.6%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES1 company5.9%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC1 company5.9% About Matthew BieglerMatt Biegler is a Senior Analyst covering Emerging Biotechnology. Prior to joining Oppenheimer, Matt worked with Mark Breidenbach covering Biotechnology. Prior to his Wall Street career, Matt spent over five years in the healthcare industry, most recently as a Consultant at Parexel International, a Contract Research Organization. His areas of expertise include clinical trial design and strategy. Matt holds a Bachelor’s degree in Biochemistry and Molecular Biology from Boston University, and a Master’s in Biotechnology from the Columbia University Graduate School of Arts and Sciences.Follow on LinkedIn Matthew Biegler's Ratings History at Oppenheimer Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsRLAYRelay Therapeutics4/28/2026Boost Price Target$14.95$18.00Outperform$0.0000.00% ROIRLAYRelay Therapeutics3/16/2026Reiterated Rating$10.13Outperform$0.0000.00% ROICTMXCytomX Therapeutics3/16/2026Reiterated Rating$7.69$12.00Outperform$0.0000.00% ROIOLMAOlema Pharmaceuticals3/9/2026Reiterated Rating$18.13Outperform$0.0000.00% ROIORICOric Pharmaceuticals2/24/2026Reiterated Rating$11.71$15.00Outperform$0.0000.00% ROIREGNRegeneron Pharmaceuticals2/2/2026Reiterated Rating$754.30$865.00Outperform$0.0000.00% ROIRLAYRelay Therapeutics1/26/2026Upgrade$7.43$14.00Outperform$0.0000.00% ROIOLMAOlema Pharmaceuticals12/11/2025Boost Price Target$32.42$48.00Outperform$0.0000.00% ROIAAPGAscentage Pharma Group International12/4/2025Initiated Coverage$30.33$45.00Outperform$0.0000.00% ROIOLMAOlema Pharmaceuticals11/18/2025Boost Price Target$19.85$45.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. ORICOric Pharmaceuticals11/14/2025Boost Price Target$12.19$15.00Outperform$0.0000.00% ROINRIXNurix Therapeutics10/10/2025Lower Price Target$10.86$28.00Outperform$0.0000.00% ROITYRATyra Biosciences9/10/2025Reiterated Rating$11.82$36.00Outperform$0.0000.00% ROIIDYAIDEAYA Biosciences9/8/2025Set Price Target$24.98$36.00Outperform$0.0000.00% ROIOLMAOlema Pharmaceuticals9/3/2025Reiterated Rating$6.23$22.00Outperform$0.0000.00% ROIACRVAcrivon Therapeutics8/14/2025Lower Price Target$1.29$8.00Outperform$0.0000.00% ROICTMXCytomX Therapeutics7/31/2025Initiated Coverage$2.32$7.00Outperform$0.0000.00% ROINRIXNurix Therapeutics7/31/2025Reiterated Rating$11.88$30.00Outperform$0.0000.00% ROINRIXNurix Therapeutics7/10/2025Lower Price Target$12.85$30.00Outperform$0.0000.00% ROIACRVAcrivon Therapeutics5/15/2025Lower Price Target$1.14$9.00Outperform$0.0000.00% ROIALLOAllogene Therapeutics5/14/2025Lower Price Target$0.90$9.00Outperform$0.0000.00% ROIOLMAOlema Pharmaceuticals5/14/2025Lower Price Target$4.43$22.00Outperform$0.0000.00% ROIORICOric Pharmaceuticals5/6/2025Lower Price Target$5.70$12.00Outperform$0.0000.00% ROIVORVor Biopharma3/21/2025Reiterated Rating$17.28$160.00Outperform$00.0000.00% ROIOLMAOlema Pharmaceuticals3/19/2025Reiterated Rating$4.18$25.00Outperform$00.0000.00% ROIARVNArvinas2/12/2025Boost Price Target$17.91$45.00Outperform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James FinancialStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
